While the anti-LILRB2 antibody was not effective, the anti-LILRB1 antibody enhanced ADCP considerably, but strictly required simultaneous CD47 blockade and the presence of a tumor targeting CD20 antibody to become effective. Here, LILRB2 is linked to neoplasm.